Key Amgen Pipeline Readouts in 2024

The biotechnology giant presented an impressive range of new drugs, highlighting advancements in different therapeutic areas signaling a strong future trajectory for the company (FIG. 1). General Medicine

MariTide: Obesity Ph2 data readout in Late 2024.

AMG 786: Obesity Ph1 data readout in H1 2024.

Inflammation

Rocatinlimab: Atopic Dermatitis Ph3 data readout in H2 2024.

TEZSPIRE: Chronic rhinosinusitis w/ nasal polyps Ph3 data readout in H2 2024.

TEZSPIRE: COPD Ph2 data readout in H1 2024.

Rare Disease

UPLIZNA: Myasthenia gravis Ph3 data readout in H2 2024.

UPLIZNA: IgG4-related disease Ph3 data readout in H2 2024.

AMG 670: IPF Ph2 data readout in H2 2024.

Oncology

Tarlatamab: PDUFA date of Jun. 12, 2024 for Advanced SCLC.

Nplate: Chemo-induced thrombocytopenia Ph3 data readout in H2 2024.

FIG. 1. Amgen Pipeline Activity in 2024.

Are you a CRO, CMO, or Biopharma vendor? Get a list of 100's of biopharma companies with cell therapy products. Perfect for sales and business development activities. Access our free report here: https://www.biopharmiq.com/cell-therapy-companies-report Article History: 2/1/2024 -EJV

This article is not investment or legal advice.